Dyve Biosciences
Nathan Fitzsimmons, Ph.D. joined Dyve in 2015 after spending over 5 years with McKinsey & Company consulting companies in the biotech, pharma, and medical device industries. Nathan received his Ph.D. in Neurobiology from Duke University and he also received his BSE in Biomedical Engineering from Duke University.
This person is not in any offices
Dyve Biosciences
1 followers
Dyve is a clinical-stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout.